Dr. Chandra Belani on Selecting Anti-PD-L1 Agents in Lung Cancer

Video

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses results seen with anti–PD-1/PD-L1 treatments in lung cancer.

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses results seen with anti—PD-1/PD-L1 treatments in lung cancer.

Belani says at this juncture, there is no one “winner" amongst these treatments.

Identifying a group of patients that best benefit from anti—PD-1 treatments will be the key to better understanding these agents, says Belani.

Related Videos
Angela Jia, MD, PhD, of University Hospitals
Robert Wang, MD, of Fox Chase Cancer Center
Alexander Kutikov, MD, FACS, of Fox Chase Cancer Center
Roger Li, MD, of Moffitt Cancer Center
Joshua J. Meeks, MD, PhD, of Northwestern University Feinberg School of Medicine
Neal Shore, MD, FACS, of GenesisCare USA and Carolina Urologic Research Center
Mark D. Tyson, II, MD, MPH
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Eric S. Christenson, MD